Immune to Cancer: The CRI Blog
-
ASCO 2016 Update: Advances in Immunotherapy for Lung and Blood Cancers
Combination checkpoints, improved CAR T cells show promise.
-
ASCO 2016 Update: The Value of Combination Immunotherapy
Activating multiple immune pathways to improve patient outcomes.
-
ASCO 2016 Update: The Personal Side of Immunotherapy
To help more patients, treatments must get personal.
-
Inmunoterapia vs. Quimioterapia: ¿Cual es la diferencia?
Respondemos las preguntas frecuentes de los pacientes sobre las diferencias entre la inmunoterapia y la quimioterapia, incluidos…
-
ASCO 2016: The Year of Immunotherapy
Chicago hosts top clinical cancer conference, immunotherapy shines.
-
The Evolution of Cancer Treatment: From Simplistic Strategies to Personalized Prescriptions
Immunotherapy, personalized medicine poised to revolutionize cancer treatment.
-
Author Shares Her Immunotherapy Experience in New Memoir
In her new memoir, Mary Elizabeth Williams documents her experience with metastatic melanoma, and her subsequent treatment…
-
Immunotherapy in the Spotlight
Dateline NBC took a closer look at this revolution known as immunotherapy and plans to tap into…
-
Atezolizumab (Tecentriq™) Receives FDA Approval for Bladder Cancer
It becomes the first FDA-approved checkpoint blockade immunotherapy for bladder cancer.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.